> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# vVARDIS Sets $18.00 IPO Price Below The $21.00–$24.00 Range It Marketed
- URL: https://www.bullished.co/vvardis-sets-18-00-ipo-price-below-the-21-00-24-00-range-it-marketed-2067c851/
- Published: 2026-11-13T10:26:08.000Z
- Updated: 2026-11-13T10:26:08.000Z
- Description: The $175 million base offering comes in a slower IPO market, with recent biopharma debuts showing uneven returns.
- Author: Matteo Parrino
- Tags: Deals, VVVV, Industry: Healthcare, Topic: IPOs

vVARDIS, a Swiss dental-technology company, priced its IPO at [$18.00 per share](http://www.businesswire.com/news/home/20261112546569/en/vVARDIS-Announces-Pricing-of-Initial-Public-Offering/?ref=bullished.co) Thursday, below the $21.00–$24.00 range marketed to investors. The offering is set to raise $175 million, according to the company's pricing announcement.

## A Smaller Price For The Debut

The base deal covers 9,722,223 Class A shares. vVARDIS expects the stock to [begin trading Friday](https://www.afp.com/en/agency/inside-afp/external-press-releases/vvardis-announces-pricing-initial-public-offering?ref=bullished.co) on the New York Stock Exchange with the ticker VVVV.

Underwriters have a [30-day option](http://www.businesswire.com/news/home/20261112546569/en/vVARDIS-Announces-Pricing-of-Initial-Public-Offering/?ref=bullished.co) to buy up to 1,458,333 additional Class A shares at the IPO price. Those shares are separate from the $175 million base offering.

Goldman Sachs and J.P. Morgan headed the underwriting group, joined by William Blair, UBS Investment Bank and Deutsche Bank Securities. The Securities and Exchange Commission declared the offering's registration effective Thursday.

## Curodont Meets A Slower IPO Market

Based in Zug, Switzerland, vVARDIS sells [Curodont dental products](https://www.afp.com/en/agency/inside-afp/external-press-releases/vvardis-announces-pricing-initial-public-offering?ref=bullished.co). Co-founders Haley Abivardi and Goly Abivardi are its co-chief executives, according to Thursday's amended [IPO filing](https://www.sec.gov/Archives/edgar/data/1907709/000114036126043309/ny20076472x16%5Ff1a.htm?ref=bullished.co).

The listing comes as IPO activity has fallen. Renaissance Capital counted [121 priced IPOs](https://inv-prd.institutionalinvestor.com/index%2ephp/article/its-biopharma-or-bust-ipo-market?ref=bullished.co) through Tuesday, down 36% from 2025.

Biopharma accounted for seven of October's nine new listings, putting healthcare businesses at the center of that month's activity. But only two of those seven stocks traded above their offering prices as of Tuesday.

The vVARDIS offering is expected to close on or about Monday.

Learn

- [IPO Lockup Period Meaning: What Insiders Can Sell, When, And Where To See It →](https://www.bullished.co/learn/ipo-lockup-period-meaning/)  
An IPO lockup bars insiders from selling shares for a set period. Learn how to find the terms, what expiration means, and how insider sales are filed.

### Sources

- [vVARDIS Announces Pricing of Initial Public Offering](http://www.businesswire.com/news/home/20261112546569/en/vVARDIS-Announces-Pricing-of-Initial-Public-Offering/?ref=bullished.co) — Business Wire
- [vVARDIS Announces Pricing of Initial Public Offering | AFP.com](https://www.afp.com/en/agency/inside-afp/external-press-releases/vvardis-announces-pricing-initial-public-offering?ref=bullished.co) — afp.com
- [https://www.sec.gov/Archives/edgar/data/1907709/000114036126043309/ny20076472x16\_f1a.htm](https://www.sec.gov/Archives/edgar/data/1907709/000114036126043309/ny20076472x16%5Ff1a.htm?ref=bullished.co) — sec.gov
- [It’s Biopharma or Bust for the IPO Market | Institutional Investor](https://inv-prd.institutionalinvestor.com/index%2ephp/article/its-biopharma-or-bust-ipo-market?ref=bullished.co) — inv-prd.institutionalinvestor.com